Teva Pharmaceutical Industries LTD

Teva Pharmaceutical Finance Netherlands II B.V. and other subsidiaries have issued new senior notes in Euro and USD denominations, totaling billions, to refinance existing debt and for general corporate purposes.

Teva Pharmaceutical Industries Ltd. has transitioned its ordinary shares to trade directly on the New York Stock Exchange, replacing its American Depositary Shares (ADSs) program.

Teva Pharmaceutical Industries Ltd. announced the successful pricing of approximately $4.9 billion (equivalent) in senior notes, aimed at refinancing existing debt and funding redemptions.

Teva Pharmaceutical Industries Ltd. announced robust second-quarter 2026 financial results, driven by significant growth in its key innovative brands, leading to an upward revision of its full-year outlook.

Teva Pharmaceutical Industries Limited shareholders approved the election of Dr. Sol J. Barer to the Board and ratified executive compensation and auditor appointments.

Teva Pharmaceutical Industries Ltd. announced robust first-quarter 2026 financial results driven by its innovative portfolio and disciplined execution, alongside a definitive agreement to acquire Emalex Biosciences for its neuroscience pipeline.

Teva Pharmaceutical Industries Limited announced amendments to its deposit agreement and the termination of its American Depositary Shares (ADS) program, with ordinary shares to be directly listed on the NYSE.

Teva Pharmaceutical Industries Limited reported a significant turnaround in Q3 2025, achieving net income and operating profit, driven by strong U.S. segment performance and substantial debt reduction.

Teva Pharmaceutical Industries Limited announced a significant increase in operating income and net income for the second quarter of 2025, driven by robust performance in its U.S. segment and strategic debt management, despite a slight revenue decrease in local currency terms.

Teva Pharmaceutical Industries reports a 2% increase in revenue for Q1 2025, driven by growth in AUSTEDO, generics, and AJOVY, while progressing with its Pivot to Growth strategy.

Teva Pharmaceutical Industries reported a 13% increase in revenue for the third quarter of 2024, but also faced a significant goodwill impairment and increased legal expenses.

Teva Pharmaceutical Industries reports a 7% revenue increase in Q2 2024, but also records a significant goodwill impairment charge.

Teva Pharmaceutical Industries Limited reported a 4% increase in 2025 revenues, driven by strong performance in key innovative products and strategic pipeline advancements, despite declines in certain generic markets.

Teva Pharmaceutical Industries navigates a year of strategic transformation, showcasing growth in key products but facing challenges in generics and legacy treatments.

Teva Pharmaceuticals extends an executive's international assignment and revises prior financial statements, highlighting a collaboration payment and sustainability-linked bond details.

Brian Savage, Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd, sold 7,342 shares of common stock on September 18, 2026.

Roberto Mignone, a Director of Teva Pharmaceutical Industries Ltd, sold 367,600 shares of common stock on September 19, 2026 for $39.06 per share.

Ronit Satchi-Fainaro, a Director of Teva Pharmaceutical Industries Ltd, sold 415 shares of common stock on August 21, 2026 for $37.25 per share.

Evan Lippman, EVP, Business Development of Teva Pharmaceutical Industries Ltd, sold 18,600 shares of common stock on August 17, 2026 for $36.57 per share.

Tal Zvi Zaks, a Director of Teva Pharmaceutical Industries Ltd, sold 17 shares of common stock on August 5, 2026 for $34.87 per share.

Teva Pharmaceutical Industries Ltd. CFO Eliyahu Sharon Kalif sold a portion of his holdings in ordinary shares as part of a pre-arranged trading plan.

Teva Pharmaceutical Industries Limited reports strong 2025 performance, advancing its 'Pivot to Growth' strategy with significant gains in innovative medicines and debt reduction, while outlining ambitious 2026 goals.

Teva Pharmaceutical Industries Limited will hold its annual shareholder meeting virtually on June 5, 2025, to vote on director elections, executive compensation, and other key proposals.

Teva Pharmaceutical Industries is asking shareholders to vote on key proposals at its upcoming annual meeting, including the election of directors, executive compensation, and amendments to director compensation policies.

Teva Pharmaceutical Industries Limited will hold its annual shareholder meeting virtually on June 6, 2024, to vote on director appointments, executive compensation, and auditor selection.

Teva Pharmaceutical's proxy statement highlights the company's 'Pivot to Growth' strategy, board refreshment, and key proposals for the 2024 annual meeting.

Migdal Insurance & Financial Holdings Ltd. has reported a beneficial ownership of 5.37% in Teva Pharmaceutical Industries Ltd. as of December 31, 2025.

Harel Insurance Investments & Financial Services Ltd. has reported a 6.3% beneficial ownership stake in Teva Pharmaceutical Industries Ltd. as of December 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 2.1% beneficial ownership stake in Teva Pharmaceutical Industries Ltd. as of September 30, 2025.

Harel Insurance Investments & Financial Services Ltd has reported a 5.1% beneficial ownership stake in Teva Pharmaceutical Industries Ltd, primarily held on behalf of public and client accounts.

FMR LLC and Abigail P. Johnson report a 5.1% beneficial ownership of Teva Pharmaceutical Industries Ltd. common stock.

Phoenix Financial Ltd. has reported a 5% beneficial ownership stake in Teva Pharmaceutical Industries Ltd., holding over 57 million ordinary shares.